Corbus Pharmaceuticals Presents Phase 1B Canyon-1 Clinical Trial Data For Crb-913 At Obesityweek® 2026
Nov 16 (Reuters) - Corbus Pharmaceuticals Holdings, Inc. CRBP.O:
CORBUS PHARMACEUTICALS PRESENTS PHASE 1B CANYON-1 CLINICAL TRIAL DATA FOR CRB-913 AT OBESITYWEEK® 2026
CORBUS PHARMACEUTICALS HOLDINGS - NO SERIOUS OR SEVERE PSYCHIATRIC ADVERSE EVENTS REPORTED WITH CRB-913
Further company coverage: CRBP.O